The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y

• Published in: Radiotherapy and oncology Vol. 21; no. 2; pp. 91 - 99
• Main Authors: Wheldon, T E, O'Donoghue, J A, Barrett, A, Michalowski, A S
• Format: Journal Article
• Language: English
• Published: Ireland 01.06.1991
• Subjects: Beta Particles; Dose-Response Relationship, Radiation; Humans; Iodine Radioisotopes - therapeutic use; Models, Theoretical; Neoplasms - pathology; Neoplasms - radiotherapy; Prognosis; Yttrium Radioisotopes - therapeutic use
• ISSN: 0167-8140
• DOI: 10.1016/0167-8140(91)90080-Z

A mathematical model has been used to investigate the relationship of curability to tumour size and cell number for spherical tumours treated with targeted 131I or 90Y, assuming uniform uptake of radionuclide throughout the tumour. The analysis shows that, for any given cumulated activity per unit mass of tumour, cure probability is greatest for tumours whose diameter is close to an optimum value which depends on the path length of the emitted beta-particle. Smaller tumours are less curable because of inefficient absorption of radiation energy, and larger tumours are less curable because of greater clonogenic cell number. The lesser curability of very small tumours is a feature of targeted radiotherapy using long-range beta-emitters which does not occur with external beam irradiation. The predicted inefficiency of sterilisation of microscopic tumours poses a problem for targeted radiotherapy which is analogous to "geographic miss" in conventional radiotherapy. The implication is that small micro-metastases could escape sterilisation by radionuclides administered at activity levels sufficient to eradicate larger tumours. It is suggested that single agent targeted radiotherapy should not be used for treatment of disseminated malignancy when multiple tumours of differing size, including micrometastases, may be present. The analysis implies that an advantage might result from the use of a panel of several radionuclides (including short-range emitters) or from combining targeted radiotherapy using long-range beta-emitters with external beam irradiation or some other modality to which microscopic tumours are preferentially vulnerable.